The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Off-the-shelf CAR T-cell therapy
In this interview, Dietmar Berger, MD, PhD, of Atara Biotherapeutics, San Francisco, CA, discusses the current limitations of CAR T-cells. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Berger introduces the exciting next generation, off-the-shelf CAR T-cell products, which can be utilized in the allogeneic setting. Dr Berger talks through the many advantages of this, before revealing the use of these CAR T-cells, notably in B-cell malignancies and acute myeloid leukemia (AML).
